13:00 ETArna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform

Arna Pharma Inc. and Slate Run Pharmaceuticals have signed a Memorandum of Understanding (MOU) to establish a joint venture aimed at creating a scaled-up U.S. specialty pharmaceutical platform. This collaboration will leverage Arna's development capabilities and Slate Run's commercial and regulatory infrastructure to focus on branded products, 505(b)(2) medicines, and specialized generics. The joint venture is expected to enhance market access and accelerate the introduction of specialized generics in high-value therapeutic segments. Leadership from both companies will ensure seamless integration and uphold regulatory compliance and product quality standards.